Different Gut and Blood Metabolites in Children with Autism and Their Changes after Microbiota Transfer Therapy

A liquid chromatography-mass spectrometry (LC-MS) assay identified a total of 619 metabolites in our plasma samples (see Data Set S1, Tab 1, in the supplemental material). To evaluate differences in metabolite profiles as a group, we generated a heat map and performed a principal-component analysis (PCA) using the 73 plasma metabolites whose levels were relatively different at baseline between the two groups (unadjusted P < 0.05). Figure 1b displays the results of the PCA for each participant in the ASD group at 3 time points and for the TD group. The plot shows that the ASD group cluster at baseline was significantly separated from the TD group cluster at baseline (adjusted P < 0.01 by permutational multivariate analysis of variance [PERMANOVA]; 12 of 18 ASD samples in leftmost cluster, whereas the TD group is in the rightmost cluster). After vancomycin treatment (at 3 weeks), the ASD group shifted toward the TD group (only 4 of 18 in leftmost cluster) and further shifted toward the TD group after MTT at week 10 (0 of 18 in leftmost cluster) (Fig. 1b and c). The heat map presented in Fig. 1d shows the metabolites’ normalized relative intensities for the ASD group at three different time points and the normalized relative intensity of the TD group at baseline. As shown in the heat map with the dendrogram in Fig. 1d, the 73 plasma metabolites were clustered into two groups, based on whether they were initially higher (clusters 1 and 2) or lower (clusters 3, 4, and 5) at baseline and whether they increased/decreased (clusters 1, 3, and 4) or were maintained (clusters 2 and 5) after MTT. Cluster 1 (Fig. 1d) included 23 metabolites which displayed higher levels of normalized relative intensity in ASD samples at baseline and became more similar to levels in TD samples after MTT at week 10. Cluster 2 included 12 metabolites that were initially higher in the ASD samples but did not change significantly after treatment. Clusters 3 and 4 (defined as identical but placed separately in Fig. 1d) consisted of 25 metabolites which were lower in the ASD samples at baseline and increased after MTT. Metabolites in cluster 5 were lower at baseline but unchanged after MTT.

To identify potentially important metabolites, we performed Mann-Whitney U tests for all 619 plasma metabolites and corrected their P values for multiple hypotheses by using two separate multiple-hypotheses correction tests (Benjamini-Hochberg and leave-one-out methods). Of 619 metabolites, 9 plasma metabolites were significantly different at baseline between the ASD and TD groups by both correction tests (Table 1) (adjusted P < 0.05). Nicotinamide riboside and IMP were the two most significantly different metabolites at baseline based on Benjamini-Hochberg and leave-one-out correction, and both were significantly lower in the ASD group than in the TD group. Amino acid products (sarcosine and methylsuccinate), dipeptides (valylglycine and leucylglycine), galactonate, and iminodiacetate were significantly lower in ASD samples, whereas caprylate (medium-chain fatty acids with 8 carbon atoms; C₈) was significantly higher in ASD samples (Table 1) (adjusted P < 0.05).

Notably, most metabolites listed above significantly changed after treatment. Sarcosine, methylsuccinate, nicotinamide riboside, IMP, leucylglycine, and iminodiacetate were significantly lower in ASD samples at baseline and increased significantly after vancomycin at week 3 and remained increased after MTT at week 10 compared to baseline (Table 2 and Fig. 1d) (one-tailed Wilcoxon rank test P < 0.05, clusters 3 and 4). In contrast, caprylate and heptanoate were significantly higher in ASD samples at baseline and significantly decreased after MTT at week 10 (P < 0.05; cluster 1) (Fig. 1d). Only two metabolites (galactonate and valylglycine) in Table 2 did not change significantly. Galactonate was significantly lower in the ASD group than in the TD group at baseline but did not increase after MTT. Valylglycine was significantly lower in the ASD group than in the TD group at baseline, increased at week 3, but returned to its original level at week 10 (Tables 1 and 2). Overall, 8 of 10 abnormal metabolites shifted significantly after MTT so that they became closer to the levels in the TD group, and the other two partially shifted.

Although not significant after multiple-hypotheses correction, several metabolites that were previously reported as abnormal in either humans or an animal model (8, 26, 33–35) were either relatively higher or lower than in the TD group (see Table S1). We were interested in neurotransmitters (glutamate, GABA, dopamine, and serotonin), tyrosine/tryptophan derivatives (such as p-cresol, 4-ethylphenyl sulfate [4-EPS], and indole), and antioxidants (such as glutathione, biliverdin, and bilirubin). The levels of normalized relative intensities were relatively higher for glutamate and lower for indolepropionate, biliverdin, and bilirubin in the ASD group at baseline (two-tailed unadjusted P < 0.05). After MTT at week 10, glutamate and indole propionate changed toward that in the TD group (Table S1).

In fecal samples, we identified 669 metabolites in total (Data Set S1, Tab 2). To evaluate differences in metabolite profiles as a group, we first performed PCA and heat map analysis for the 26 metabolites whose levels were most different at baseline between the two groups (unadjusted P < 0.05). As shown in Fig. 1e, PCA results showed that the fecal metabolites of the ASD and TD groups were similar at baseline and remained similar after MTT. Figure 1f shows that there were no significant differences between ASD and TD groups at baseline, and no significant change was observed between baseline and after MTT.

We also investigated individual levels of fecal metabolites, but of 669 metabolites, no metabolite was significantly different after correcting for multiple hypotheses (adjusted P > 0.05). Although not statistically significant, three tyrosine derivatives (p-cresol sulfate, tyramine O-sulfate, and 4-hydroxyphenylacetate) and indole, a serotonin precursor, were relatively different at baseline (unadjusted P < 0.05) (see Table S2). p-Cresol sulfate, 4-hydroxyphenylacetate, and indole levels were relatively higher in feces from the ASD group at baseline, whereas tyramine O-sulfate, a metabolite that has similar chemical structure to those of 4-EPS and p-cresol sulfate, was relatively lower in feces from the ASD group. After MTT, p-cresol sulfate levels were lowered to levels similar to those of the TD group, and the other metabolites mentioned above did not change toward those in the TD group (Table S2).

With 16S rRNA gene amplicon sequencing data (28), PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved state) (36) and HUMAnN (the HMP unified metabolic analysis network) (37) analyses predicted 116 microbial function modules in total throughout the samples (Data Set S1, Tab 3). However, none of the functional modules identified showed statistical significance after correcting for multiple-hypotheses testing.

Figure 2a displays the plasma metabolites that had the most significant correlations (Spearman correlation coefficient |r| > 0.5) with clinical assessments of GI and ASD-related symptoms. IMP levels were strongly negatively correlated with GI assessments via the gastrointestinal symptom rating scale (GSRS) and daily stool record (DSR) (a black-dotted circle in Fig. 2a and c); in other words, the increase of IMP levels to normal levels after MTT was strongly associated with improvements in GI symptoms. Methylsuccinate was strongly correlated with parental global impressions-revised (PGI-R) (Spearman correlation, |r| = 0.75) (Fig. 2a and d), i.e., the increase of methylsuccinate to normal levels after MTT was strongly associated with improvements in ASD-related symptoms. For plasma metabolites and the three gut bacteria (Bifidobacterium, Prevotella, and Desulfovibrio), we only found one significant correlation between Bifidobacterium and 5-(galactosylhydroxy)-l-lysine (r = 0.54, P < 0.01).

Figure 3a shows a correlation-based network analysis between fecal metabolites, clinical measurements, and three bacteria (Bifidobacterium, Prevotella, and Desulfovibrio), which were the three gut microbes which significantly changed in response to MTT (28). Correlation-based network analyses shows that Bifidobacterium is strongly correlated with many stool metabolites, especially negatively correlated with amino acids/peptides (arginine, asparagine, isoleucylglycine, and valylleucine) and nucleotides (adenosine, xanthosine, and inosine) (Fig. 3a). In contrast, sulfate-reducing Desulfovibrio was not strongly correlated with metabolites of interest, but there was a modest significant negative correlation with p-cresol sulfate and sulfate (Fig. 3b and c). p-Cresol sulfate and sulfate levels were strongly and significantly correlated with each other (Fig. 3d). GI and behavioral symptoms were associated with several metabolites, but those metabolites were not correlated with any of the three bacteria, suggesting that other bacteria (or subsets of those bacteria) are affecting the metabolites associated with GI and ASD symptoms.

For plasma metabolites, when we consider 75 metabolites whose levels were relatively different at baseline between the two groups (unadjusted P < 0.05), PCA found that the ASD group cluster (12 of 18 samples) was significantly separate from the TD group at baseline (adjusted P < 0.01 by PERMANOVA), but after vancomycin (week 3) and after 10 weeks of MTT, the ASD group was closer (while not completely similar) to the TD group (Fig. 1b and c). The heat map analysis (Fig. 1d) shows that many individual metabolites that were initially higher (cluster 1, n = 23) or lower (clusters 3 and 4, n = 25) in ASD shifted toward more normal levels after MTT; however, some metabolites with abnormal levels at baseline did not improve (clusters 2 and 5, n = 25). These individual shifts explain changes in the PCA (Fig. 1b). At baseline, 6 children with ASD already had similar plasma metabolite profiles to the one after MTT (Fig. 1b), and those ASD samples (ASD6, ASD9, ASD10, ASD11, ASD12, and ASD16) had lower levels of nicotinamide riboside, methylsuccinate, iminodiacetate, and sarcosine at baseline (in cluster 3) and higher levels of caprylate, azelate, heptanoate, and caproate at baseline (in cluster 1) than the other 12 ASD samples at baseline. At week 3, 8 children with ASD experienced a shift in their plasma metabolites toward those of the TD group, reflecting a potential role of antibiotics and a proton pump inhibitor changing the gut microbiome.

After correcting for multiple hypotheses, we found 10 plasma metabolites that were significantly different in ASD versus controls at baseline (Table 1). Nicotinamide riboside was significantly lower in ASD samples, and their levels significantly increased after MTT (Tables 1 and 2). Nicotinamide riboside is a pyridine nucleoside form of vitamin B₃ and a precursor for NAD (38, 39), a critical molecule involved in hundreds of redox and other reactions. Typically, tryptophan or aspartate are converted to NAD, but an alternative path involves the synthesis of NAD from nicotinamide riboside (salvage pathways) when the normal pathway is blocked. NAD levels were found to be significantly lower in children with ASD in another study (34) and found to increase significantly after treatment with a vitamin/mineral supplement (22) or by supplementation with NADH or ribose (40). Nicotinamide riboside supplementation prevented neurological damage and improved cognitive and physical function in an Alzheimer’s disease model (41). Intriguingly, nicotinamide riboside in plasma samples is positively correlated with tryptophan derivatives, indolepropionate (or indole-3-propionate), and methylsuccinate (Fig. 2b). Indolepropionate helps maintain mucosal homeostasis and is a neuroprotective antioxidant, which is consistent with our findings of low levels in the ASD group before MTT but normal levels after MTT (42). Methylsuccinate is a competitive inhibitor of succinate dehydrogenase that is involved in the GABA shunt and reactive oxygen stress (ROS) homeostasis (43). Methylsuccinate was strongly positively correlated with PGI-R and negatively correlated with GSRS (r = −0.51), consistent with improvements in ASD and GI symptoms after MTT.

IMP and sarcosine levels were significantly lower in the ASD group at baseline and increased after MTT; that increase was strongly correlated with improvements in GI symptoms (GSRS and DSR) (Fig. 2c). We did not find significant correlation between IMP and sarcosine, but these two metabolites together with tyramine O-sulfate were the most promising combination to distinguish between TD and ASD with GI symptom groups from a multivariate analysis (32). IMP is involved in NAD-dependent oxidation that converts IMP and NAD⁺ to xanthosine monophosphate and NADH (IMP dehydrogenase). IMP dehydrogenase activity was suggested to be related to irritable bowel disease (44). IMP was significantly and positively correlated with 3-phosphoglycerate (3PG) and oxidized glutathione (Fig. 2b). We did not find a meaningful metabolic relation between these three metabolites, but 3PG is linked to energy generation in mitochondria and folate metabolism (45). Glutathione is an antioxidant which can neutralize ROS and has many important roles in the body, including detoxification and immune function (46). In a previous study (47), reduced glutathione (GSH) levels were lower in plasma samples of children with ASD, and a redox ratio of reduced to oxidized glutathione (GSH:GSSG) was lower than that in typically developing children. In our plasma samples, oxidized glutathione (GSSG) levels were comparable between groups at baseline. Since reduced glutathione was not measured in our analysis, the redox ratio of glutathione was not available to compare with the previous study. Sarcosine, also called N-methylglycine, is converted to glycine that has a vital wide-ranging role in human physiology, including in nucleic acid synthesis and central nervous system homeostasis (48). Sarcosine supplementation is beneficial for depression and schizophrenia (49).

Caprylate and heptanoate are medium-chain fatty acids (MCFAs) that were highly correlated with one another (r = 0.79). The ASD group had average levels of caprylate and heptanoate at baseline that were 190% and 590% above normal, respectively, and decreased to normal levels after MTT. They were both significantly correlated with the PGI-R (r = −0.58 and −0.66), so that their decrease after MTT was correlated with an improvement in ASD symptoms. Galactonate is formed by oxidation of galactose, possibly by galactose dehydrogenase (50). At baseline, the level of galactonate was significantly lower in the ASD group, suggesting impaired production. Another study, however, found that galactonate was higher in children with ASD (51).

Glutamate levels were relatively higher in ASD plasma samples at baseline. This observation is consistent with what we expected, because glutamate is a major excitatory neurotransmitter that has been related to anxiety and excitation, which are behavioral symptoms that children with ASD experience (52, 53). Bilirubin and its oxidized form biliverdin possess antioxidant properties (54, 55), and their relative intensities were relatively lower in plasma samples from the ASD group at baseline (see Table S1 in the supplemental material), reflecting a deficit for preventing oxidative stress in children with ASD (56–58). MTT, however, did not change bilirubin and biliverdin levels toward those in TD group plasma samples (Table S1); therefore, these may be a useful target for other future therapies.

Although not significant after controlling for multiple-hypotheses testing, p-cresol sulfate levels were relatively higher in the ASD group and decreased toward normal levels after MTT (see Table S2), which is in line with what we expected. Elevated p-cresol sulfate induces oxidative stress (59), and tyrosine metabolism along with p-cresol has been implicated in the etiology of ASD through human and animal studies (60, 75). A previous study with an autism mouse model claimed p-ethylphenyl sulfate (4-EPS) as an important metabolite associated with autism symptoms and pointed out its similar chemical structure to that of p-cresol sulfate, a uremic toxin (26). Axial Biotherapeutics has reported elevated concentrations of 4-EPS in children with ASD (61). We previously reported higher p-cresol concentrations in ASD fecal samples (8), and in this study, we observed higher but not statistically significant p-cresol levels in ASD fecal samples (Table S2). Notably, the decrease in p-cresol sulfate after MTT was modestly but significantly associated with the increase in Desulfovibrio (Fig. 3b). Desulfovibrio has not been listed as a beneficial microbe but rather has been accepted as a detrimental one in the view of the autism phenotype (11, 13, 18, 62); however, we found it significantly increased after MTT at week 10, suggesting it may have some beneficial role (28). Significant correlations between Desulfovibrio, p-cresol sulfate, and sulfate (Fig. 3b to d) support a potential role for sulfate-reducing microbes such as Desulfovibrio in the metabolism of p-cresol sulfate (63). Regarding 4-EPS, we only identified 4-EPS in plasma samples, and its levels were marginally lower in ASD samples (two-tailed Mann-Whitney U test P = 0.09). This observation is not consistent with Hsiao et al.’s data on mice (26), and we did not see any change after MTT. A larger study is needed to clarify if 4-EPS is relevant to human ASD.

Overall, it is intriguing that we observed significant changes in metabolic features in plasma metabolites but not much in fecal metabolites, even though we had found substantial changes in gut microbiota after MTT. This distinct result between plasma and fecal samples reflects some of the challenges of working with complex gut microbiota and their metabolites. This study relied on a small sample size with different GI disorder types (e.g., constipation, diarrhea, or abdominal pain), and a larger cohort may help differentiate subtle but important changes in fecal metabolites that could be masked in this study. Although we employed rigorous nonparametric tests for the network analysis, a larger sample size with more time points would help achieve a more robust correlation network in future studies. At baseline, p-cresol sulfate was different in our fecal samples. However, gut microbes produce p-cresol not p-cresol sulfate, and p-cresol produced by gut microbes is converted to p-cresol sulfate by host sulfation in the liver. Our observation of p-cresol sulfate may reflect its release from host to the gut, like bile acids (64), or by the systemic circulation between gut and liver (65). Further studies with multiple analytical assays are warranted to validate our observation of p-cresol sulfate.

In summary, MTT drove global changes in plasma metabolite profiles in children with ASD. Vancomycin seems to initiate a shift in the plasma metabolite profiles, but microbiota transfer resulted in further shifts and seemed to stabilize the effect of vancomycin. As a result, plasma metabolite profiles in the ASD group were modulated from being distinctly different from those in the TD group to becoming similar to those in the TD group. Among plasma metabolites that were significantly different in ASD at baseline, medium-chain fatty acids (caprylate and heptanoate) were significantly higher at baseline than in the control and significantly decreased after MTT. Nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, leucylglycine, and sarcosine were significantly lower at baseline and increased after MTT. Other metabolites such as galactonate and valylglycine were abnormal at baseline and did not improve after MTT, and so those are potential targets for other future therapies. Overall, these data provide some insight into why microbiota transplant therapy appears to be able to significantly reduce GI and ASD symptoms. It also suggests a biochemical basis for some ASD symptoms.

In contrast, for fecal metabolites, only a few metabolites were different at baseline, and none were significantly different after correction for multiple-hypotheses testing. At baseline, p-cresol sulfate, 4-hydroxyphenylacetate, tyramine O-sulfate, and indole were relatively different between groups (unadjusted P < 0.05), and only p-cresol sulfate significantly changed toward that in the TD group after MTT. There were significant correlations between p-cresol sulfate, sulfate, and Desulfovibrio, suggesting a potential role of Desulfovibrio in the metabolism of p-cresol sulfate and possible autism etiology. Further studies of fecal and blood metabolites in ASD, before and after MTT, are warranted, as well as clinical trials of other therapies, to address the metabolic changes which MTT was not able to correct.

The protocol for the original treatment study was approved by the Institutional Review Board of Arizona State University (ASU IRB protocol 00001053) and the U.S. FDA (investigational new drug number 15886), as described by Kang et al. (28). All plasma and fecal samples were collected from the 20 typically developing children and 18 children with ASD who participated in the original phase 1 trial study in accordance with the relevant guidelines and regulations, and no further inclusion or exclusion criteria were employed in addition to what we applied in the original trial (28). The consent process was initiated by communicating with past participants and their parents via email, and the study was explained in detail by phone and/or email. For the families who met the study criteria, we provided families with a copy of a child assent form and a parent permission form. After the informed consent process, families with children with ASD and typically developing children agreed to participate and signed written parent permission and assent forms. We deidentified all samples and documents for the entire study and maintained participants’ confidentiality for the entire analyses. The trial was registered at ClinicalTrials.gov (NCT02504554↗) on 30 March 2015.

The study protocol was approved by the U.S. Food and Drug Administration (FDA) (investigational new drug number 15886) and the Institutional Review Board of Arizona State University (ASU IRB protocols 00001053 and 00004890). The study population and MTT protocol are described in a previous study (28). In summary, 18 children with ASD and 20 typically developing children participated in the study. All 18 children with ASD were 7 to 16 years old and completed the 18 weeks of the open-label trial, consisting of antibiotic (vancomycin) treatment for 2 weeks, a bowel cleanse for 1 day (MoviPrep), a proton pump inhibitor (Prilosec) throughout the trial, and standardized human gut microbiota (66) of a high dose for 1 or 2 days followed by a maintenance dose for 7 to 8 weeks. We monitored participants during the 10 weeks of treatment as well as 8 weeks after MTT stopped. There were no major adverse effects. We observed substantial improvement in their GI and ASD symptoms and an increase in microbiome diversity. Further information on the clinical and microbial observations are available in the study by Kang et al. (28).

For metabolomic analysis, plasma samples were collected at baseline, week 3 (after the vancomycin and bowel cleanse, and just before the first dose of microbiota), and week 10 (the end of MTT treatment). Phlebotomists who had experience with children drew blood samples in the morning from fasting participants, centrifuged them to collect plasma samples, and froze plasma samples immediately in dry ice. Frozen samples were delivered to the laboratory and stored in a −80°C freezer until all samples were collected. Plasma samples were collected from all 18 children with ASD at three time points except for one missing sample at week 3. Plasma samples were collected from all 20 TD participants at baseline only, since they did not receive MTT. To be consistent with microbial analysis (28), we used the same fecal samples as those by Kang et al. (28) collected at baseline, week 3 to 4 (approximately 6 days after the initial high dose of microbiota), week 10, and week 18 (8 weeks after the end of MTT) for children with ASD and baseline for typically developing children. Fecal samples collected by participants at home were immediately frozen and then picked up by a student driver and delivered to the laboratory on dry ice to be stored in a −80°C freezer. Once the clinical trial concluded, the frozen samples were aliquoted and sent overnight with dry ice to Metabolon (Durham, NC, USA) for metabolomic analysis. To avoid any bias in metabolomics measurement, we randomized and blinded all autism and control samples in a random order before shipping out to Metabolon.

At Metabolon, a platform with ultrahigh performance liquid chromatography-tandem mass spectroscopy (UHPLC-MS/MS) instruments was employed. Metabolomic measurements consisted of sample extraction/preparation, quality assurance/quality control, and UHPLC-MS/MS at Metabolon, Inc., as described in detail elsewhere (67–70). Briefly, the samples were processed by mixing with methanol, vigorous strokes, and centrifugation, which allowed protein precipitation and various metabolite recovery in the supernatant (68, 70). The extracts were aliquoted, dried, and reconstituted in different solvents depending on the platform for either polar or nonpolar metabolite analyses (hydrophilic interaction liquid chromatography [HILIC]/UPLC-MS/MS or reverse-phase [RP]/UPLC-MS/MS, respectively) (69). The organic solvent was then removed by evaporation using a TurboVap (Zymark, Hopkinton, MA). The sample extracts were analyzed by the methods utilizing a Waters ACQUITY UPLC (Milford, MA) and a Thermo Scientific Q-Exactive high-resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer (Thermo Scientific, Waltham, MA). Metabolon generated deliverables, including chemical annotation, the retention time index (RI), mass, and raw area counts after metabolite quantitation. Metabolite quantitation was performed by peak area integration using the area under the curve, and the intensity measurements yielded relative intensity of each metabolite. To correct the systematic variation between measurements, data normalization was conducted at Metabolon Inc. by registering the medians to equal 1 and normalizing each data point proportionately (called the block correction). Missing values were imputed with the lowest value of each compound measurement divided by the square root of 2. With the metabolomics data sets after imputation, we normalized the relative intensity into a Z-score, which is a dimensionless quantity, to obtain a mean value of 0 and standard deviation of 1 for each individual metabolite. The Z-score indicates how many standard deviations the observation is above or below the mean and is useful to compare observations coming from different distributions of individual metabolites. Throughout the manuscript, we call these values normalized relative intensity and report all data comparing the two groups as normalized relative intensity. To calculate the ratio of the ASD group at different sampling points to the TD group at baseline (ASD/TD_baseline), each metabolite value was normalized such that the median value was set to a value of 1.0 in the TD cohort. In detail, we first obtained a median value of the TD group for each metabolite and divided all individual values of the ASD group by the TD median value. Then, we calculated each median value of the ASD group at each time point (baseline, week 3, and week 10). With those median values, we obtained the ratio between the ASD and TD groups by dividing each ASD median value by the TD median value (ASD_baseline/TD_baseline, ASD_week3/TD_baseline, and ASD_week10/TD_baseline).

To elucidate the metabolite profiles as a group, heat map analysis and principal-component analysis (PCA) were performed using the MetaboAnalyst 4.0 (71). To determine significant differences between groups, we first measured distances by the weighted Bray-Curtis matric and then performed a permutation-based nonparametric method, PERMANOVA (permutational multivariate analysis of variance), using QIIME2’s command “beta-group-significance” (72). To control multiple comparisons, we conducted 999 permutations and adjusted the P values by Benjamini-Hochberg false-discovery rate correction. For heat map analysis, the dendrogram was generated by using a hierarchical clustering method with complete linkage and “Euclidean” distance to measure the dissimilarity. To investigate how metabolites were potentially interrelated with the improvement of GI and behavioral symptoms, we performed a correlation-based network analysis with ASD samples at different time points by calculating Spearman correlation tests for ASD plasma metabolites and clinical measurements. We only considered correlations with adjusted P values of less than 0.1 after correcting for multiple hypotheses in the correlation-based network. We used Cytoscape to visualize the correlation-based network (73).

Using 16S rRNA gene amplicon sequencing data from the original study (28), we predicted microbial functions using PICRUSt v.1.1.3 (36), HUMAnN v0.99 (37), and linear discriminant analysis with effect size (LEfSe) (74) analyses available in the online Galaxy version of the Huttenhower Lab (v1.0.0). Through PICRUSt, we first obtained predicted metagenome files containing gene counts, and then we employed the PICRUSt output to HUMAnN to obtain gene and pathway summaries based on Kyoto Encyclopedia of Genes and Genomes (KEGG) modules. To investigate which bacterial functional module is associate with ASD phenotype, we performed a linear discriminant analysis with effect size (LEfSe), where the nonparametric factorial Kruskal-Wallis (KW) sum-rank test was used to detect significantly different genomic features with respect to the class of interest, ASD, and then linear discriminant analysis (LDA) was used to estimate the effect size of each individually abundant feature.

We assumed the metabolomic and 16S rRNA gene sequencing data were nonnormally distributed because of a relatively small sample size and employed nonparametric statistical tests with Mann-Whitney U test, Wilcoxon signed-rank test, Spearman correlation test, and KW sum-rank test. For metabolites and genomic features, we adjusted P values by correcting for multiple hypotheses with Benjamini-Hochberg and leave-one-out methods, and adjusted P values smaller than 0.05 were considered statistically significant. For metabolites that were previously reported and hypothesized as important, when unadjusted P values were lower than 0.05 but adjusted P values were higher than 0.05, we considered them as relatively higher or lower to indicate their relative difference between ASD and TD groups. For paired data (before and after MTT treatment in the same participants), we used the Wilcoxon signed-rank test and one-tailed test, since we hypothesized the direction of either increase or decrease of normalized relative intensity based on the measurements at baseline.

The 16S rRNA gene sequence data sets are available in the open-source sequence data repository NCBI SRA under BioProject identification (ID) PRJNA529598↗ and “Qiita” with the study ID number 10532 (https://qiita.ucsd.edu↗). The clinical data are available in the study by Kang et al. (28). Metabolomic and PICRUSt data sets are included in tables in the supplemental material.